RhumbLine Advisers
MRM

RhumbLine Advisers’s MEDIROM Healthcare Technologies MRM Stock Holding History

RhumbLine Advisers’s Portfolio MRM Stock Details MRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.22K Sell
1,984
-2,269
-53% -$3.29K ﹤0.01% 3930
2025
Q4 		$8.25K Buy
4,253
+2,946
+225% +$6.32K ﹤0.01% 3875
2025
Q3 		$2.77K Buy
1,307
+207
+19% +$347 ﹤0.01% 3961
2025
Q2 		$1.54K Buy
+1,100
New +$1.22K ﹤0.01% 4011

Other funds holding MRM

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers's MRM Position: Q1 2026 in Review

RhumbLine Advisers reduced its MEDIROM Healthcare Technologies (MRM) stake by 53% in Q1 2026, selling an estimated $3.29K and leaving 1,984 shares worth $2.22K. The position accounts for ﹤0.01% of the portfolio, ranked #3930.

RhumbLine Advisers first reported a position in MRM in Q2 2025 and has held it in 4 quarters since. The position peaked at $8.25K in Q4 2025. 5 funds tracked by Wall St. Rank hold MRM as of Q1 2026.

  • RhumbLine Advisers held 1,984 shares of MEDIROM Healthcare Technologies worth $2.22K as of Q1 2026.
  • RhumbLine Advisers sold 2,269 MEDIROM Healthcare Technologies shares in Q1 2026, an estimated $3.29K.
  • MEDIROM Healthcare Technologies made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3930 holding.
  • RhumbLine Advisers first reported a position in MEDIROM Healthcare Technologies in Q2 2025 and has held it in 4 quarters since.
  • RhumbLine Advisers's MEDIROM Healthcare Technologies position peaked at $8.25K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held MEDIROM Healthcare Technologies as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.